HUP0304039A2 - Eljárás CETP-inhibitorok előállítására - Google Patents

Eljárás CETP-inhibitorok előállítására

Info

Publication number
HUP0304039A2
HUP0304039A2 HU0304039A HUP0304039A HUP0304039A2 HU P0304039 A2 HUP0304039 A2 HU P0304039A2 HU 0304039 A HU0304039 A HU 0304039A HU P0304039 A HUP0304039 A HU P0304039A HU P0304039 A2 HUP0304039 A2 HU P0304039A2
Authority
HU
Hungary
Prior art keywords
methods
cetp inhibitors
production
preparing
preparing cetp
Prior art date
Application number
HU0304039A
Other languages
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Robert William Scott
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0304039A2 publication Critical patent/HUP0304039A2/hu
Publication of HUP0304039A3 publication Critical patent/HUP0304039A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Abstract

A találmány az (IA) és (IB) képletű koleszteril-észter transzferprotein (CETP) inhibitorok előállítására és az előállításábanalkalmazott a (VIIIA) képletű és a (VIIIB) általános képletűköztitermékre, utóbbi képletben R1 jelentése adott esetbenhelyettesített benzilcsoport, valamint ezek előállítására vonatkozik. Ó
HU0304039A 2001-04-30 2002-04-08 Methods for preparing cetp inhibitors HUP0304039A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30
PCT/IB2002/001214 WO2002088085A2 (en) 2001-04-30 2002-04-08 Methods and intermediates for preparing 4-aminoquinoline cetp inhibitors

Publications (2)

Publication Number Publication Date
HUP0304039A2 true HUP0304039A2 (hu) 2004-03-29
HUP0304039A3 HUP0304039A3 (en) 2005-10-28

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0304041A HU225777B1 (en) 2001-04-30 2002-04-08 Compounds useful as intermediates for 4-aminoquinoline derivatwes and process for producing them
HU0304039A HUP0304039A3 (en) 2001-04-30 2002-04-08 Methods for preparing cetp inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0304041A HU225777B1 (en) 2001-04-30 2002-04-08 Compounds useful as intermediates for 4-aminoquinoline derivatwes and process for producing them

Country Status (25)

Country Link
US (3) US6600045B2 (hu)
EP (2) EP1425270B1 (hu)
JP (2) JP3924251B2 (hu)
KR (2) KR100591998B1 (hu)
CN (3) CN100357265C (hu)
AR (3) AR036331A1 (hu)
AT (2) ATE321755T1 (hu)
AU (1) AU2002253448B2 (hu)
BR (2) BR0209291A (hu)
CA (2) CA2445623A1 (hu)
CZ (2) CZ20032900A3 (hu)
DE (2) DE60210265T2 (hu)
DK (2) DK1425270T3 (hu)
ES (2) ES2256461T3 (hu)
HK (1) HK1062294A1 (hu)
HU (2) HU225777B1 (hu)
IL (2) IL157544A0 (hu)
MX (2) MXPA03009936A (hu)
PL (2) PL366700A1 (hu)
PT (1) PT1425270E (hu)
RU (2) RU2259355C2 (hu)
TW (1) TWI250974B (hu)
WO (2) WO2002088085A2 (hu)
YU (2) YU84303A (hu)
ZA (2) ZA200306599B (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
WO2004074255A2 (en) * 2003-02-18 2004-09-02 Takasago International Corporation Method for producing an optically active tetrahydroquinoline
WO2004083166A1 (ja) * 2003-03-17 2004-09-30 Kaneka Corporation （ｒ）－３－［４－（トリフルオロメチル）フェニルアミノ］－ペンタン酸アミド誘導体の製造法
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
MXPA06003357A (es) 2003-09-26 2006-06-08 Japan Tobacco Inc Metodo para inhibir la produccion de lipoproteina remanente.
DK1670768T3 (da) * 2003-10-08 2009-11-09 Lilly Co Eli Forbindelser og fremgangsmåder til at behandle dyslipidæmi
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
AR048528A1 (es) * 2004-04-07 2006-05-03 Millennium Pharm Inc Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
UA90706C2 (ru) 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
BRPI0611838A2 (pt) * 2005-06-20 2012-08-28 Astrazeneca Ab processo para a preparação de um composto
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
AU2012243583B2 (en) 2011-04-12 2015-10-22 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for CETP inhibitor
AU2012282109B2 (en) * 2011-07-08 2016-06-23 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
EP2943474B1 (en) 2013-01-31 2017-07-05 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
WO2015067405A1 (en) * 2013-11-11 2015-05-14 Lonza Ltd Method for preparation of cyano compounds of the 13th group with a lewis acid
US10112904B2 (en) * 2014-08-12 2018-10-30 Dezima Pharma B.V. Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE316532T1 (de) 1998-07-10 2006-02-15 Massachusetts Inst Technology Liganden für metalle und metall-katalysiertes verfahren
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.

Also Published As

Publication number Publication date
EP1425270A2 (en) 2004-06-09
EP1383734B1 (en) 2006-02-01
EP1383734A2 (en) 2004-01-28
WO2002088069A9 (en) 2003-12-04
CZ20032898A3 (cs) 2004-07-14
CN1267411C (zh) 2006-08-02
DE60210265D1 (de) 2006-05-18
IL157544A0 (en) 2004-03-28
WO2002088085A2 (en) 2002-11-07
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
AU2002253448B2 (en) 2007-07-05
WO2002088085A3 (en) 2004-03-25
US6600045B2 (en) 2003-07-29
KR100591998B1 (ko) 2006-06-22
ATE321755T1 (de) 2006-04-15
WO2002088069A2 (en) 2002-11-07
US20020177716A1 (en) 2002-11-28
WO2002088069A3 (en) 2003-02-20
ATE316957T1 (de) 2006-02-15
RU2003131870A (ru) 2005-01-27
DE60210265T2 (de) 2006-10-12
US20030216576A1 (en) 2003-11-20
TWI250974B (en) 2006-03-11
CN1297541C (zh) 2007-01-31
ES2256461T3 (es) 2006-07-16
CN1529696A (zh) 2004-09-15
BR0209291A (pt) 2004-07-13
ES2259080T3 (es) 2006-09-16
CN1680292A (zh) 2005-10-12
PT1425270E (pt) 2006-07-31
CZ20032900A3 (cs) 2004-06-16
DE60209004T2 (de) 2006-09-28
US20030073843A1 (en) 2003-04-17
HU225777B1 (en) 2007-08-28
HUP0304041A2 (hu) 2004-04-28
RU2265010C2 (ru) 2005-11-27
CA2445693A1 (en) 2002-11-07
HK1062294A1 (en) 2004-10-29
CN100357265C (zh) 2007-12-26
DK1425270T3 (da) 2006-07-03
EP1425270B1 (en) 2006-03-29
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
PL366700A1 (en) 2005-02-07
YU84403A (sh) 2006-08-17
ZA200306599B (en) 2004-10-22
CN1505609A (zh) 2004-06-16
IL157546A0 (en) 2004-03-28
US6689897B2 (en) 2004-02-10
JP3924251B2 (ja) 2007-06-06
AR035963A1 (es) 2004-07-28
PL366584A1 (en) 2005-02-07
RU2003131871A (ru) 2005-04-10
DK1383734T3 (da) 2006-05-15
JP2004531541A (ja) 2004-10-14
HUP0304039A3 (en) 2005-10-28
JP2004527556A (ja) 2004-09-09
KR20040015200A (ko) 2004-02-18
MXPA03009935A (es) 2004-01-29
ZA200306600B (en) 2004-08-25
CA2445623A1 (en) 2002-11-07
AR044706A2 (es) 2005-09-21
HUP0304041A3 (en) 2005-08-29
DE60209004D1 (de) 2006-04-13
MXPA03009936A (es) 2004-01-29
JP3924250B2 (ja) 2007-06-06
KR100639745B1 (ko) 2006-10-30
US6706881B2 (en) 2004-03-16
YU84303A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
HUP0304039A2 (hu) Eljárás CETP-inhibitorok előállítására
CO5611065A2 (es) Difluorometiltiazolilcarboxanilidas
DK1543002T3 (da) Fremstilling af 1H-imidazo (4,5-c) quinolin-4-aminer via 1H-imidazo (4,5-c) quinolin-4-phtalimid mellemprodukter
BR9916894A (pt) ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek
HUP0401647A2 (hu) Új béta-fenil-alfa-oxi-propionsav-származékok, előállítási eljárásaik és gyógyszerészetileg fontos vegyületek előállításánál történő felhasználásuk
HK1089444A1 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
NO20025590D0 (no) Fenylglycin-derivater
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
NO20025719D0 (no) Nye triazolpyrimidinforbindelser
ATE490253T1 (de) Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen
HUP0300701A2 (hu) Zolpidem hemitartarát, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
SE0103836D0 (sv) Novel compounds
BR0305767A (pt) Métodos e composições para a preparação de derivados de ácido 4-substituìdo 3-hidroxibutìrico
BR0015836A (pt) Cristal de 4-carboxiamino-2-etil-1,2,3,4-tetra-hidroquinolina como inibidor de cetp
BR0005636A (pt) Método para a produção de 4-carboxiamino-1,2,3,4-tetrahidroquinolina 2-substituìda
HUP0204010A2 (hu) Új szertralin-hidroklorid polimorfok, eljárás az előállításukra, az új polimorfokat tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20073839L (no) Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette
DE60031886D1 (de) Purinderivate
HUP0103089A2 (hu) Beraproszt észter előállítása szelektív oxidációval
ATE327987T1 (de) Methylthiophencarboxanilide
FR2854402B1 (fr) Nouveau procede et intermediaires de preparation de composes 19-nor-steroides
NO20053829D0 (no) Fremgangsmate og intermediater for fremstilling av olanzapin.
ATE319839T1 (de) Verfahren zur verbesserung der transfektionseffizienz
BRPI0406970A (pt) Modificação cristalina de um complexo de manganês

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees